nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—Homicidal ideation—Varenicline—nicotine dependence	0.0423	0.0553	CcSEcCtD
Fluvoxamine—Anger—Varenicline—nicotine dependence	0.0149	0.0194	CcSEcCtD
Fluvoxamine—Coronary artery disease—Varenicline—nicotine dependence	0.0134	0.0176	CcSEcCtD
Fluvoxamine—Withdrawal symptom—Varenicline—nicotine dependence	0.0129	0.0169	CcSEcCtD
Fluvoxamine—Hoarseness—Varenicline—nicotine dependence	0.0121	0.0158	CcSEcCtD
Fluvoxamine—Drug withdrawal syndrome—Varenicline—nicotine dependence	0.0108	0.0142	CcSEcCtD
Fluvoxamine—Peripheral vascular disorder—Varenicline—nicotine dependence	0.0108	0.0142	CcSEcCtD
Fluvoxamine—CYP2B6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0104	0.0444	CbGpPWpGaD
Fluvoxamine—Extrapyramidal symptoms—Varenicline—nicotine dependence	0.0102	0.0134	CcSEcCtD
Fluvoxamine—CYP2E1—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0102	0.0435	CbGpPWpGaD
Fluvoxamine—Hostility—Varenicline—nicotine dependence	0.00959	0.0125	CcSEcCtD
Fluvoxamine—Sexual dysfunction—Varenicline—nicotine dependence	0.00947	0.0124	CcSEcCtD
Fluvoxamine—Suicide attempt—Varenicline—nicotine dependence	0.00936	0.0122	CcSEcCtD
Fluvoxamine—CYP3A7—Xenobiotics—CYP2A7—nicotine dependence	0.00875	0.0372	CbGpPWpGaD
Fluvoxamine—Libido increased—Varenicline—nicotine dependence	0.00873	0.0114	CcSEcCtD
Fluvoxamine—Vaginal discharge—Varenicline—nicotine dependence	0.00873	0.0114	CcSEcCtD
Fluvoxamine—Toothache—Varenicline—nicotine dependence	0.00873	0.0114	CcSEcCtD
Fluvoxamine—Psoriasis—Varenicline—nicotine dependence	0.00845	0.011	CcSEcCtD
Fluvoxamine—Parosmia—Varenicline—nicotine dependence	0.00819	0.0107	CcSEcCtD
Fluvoxamine—CYP2B6—Fatty acids—CYP2A7—nicotine dependence	0.00815	0.0347	CbGpPWpGaD
Fluvoxamine—Upset stomach—Varenicline—nicotine dependence	0.0081	0.0106	CcSEcCtD
Fluvoxamine—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00789	0.0336	CbGpPWpGaD
Fluvoxamine—Menstrual disorder—Varenicline—nicotine dependence	0.00779	0.0102	CcSEcCtD
Fluvoxamine—Paranoia—Varenicline—nicotine dependence	0.00779	0.0102	CcSEcCtD
Fluvoxamine—Intestinal obstruction—Varenicline—nicotine dependence	0.00779	0.0102	CcSEcCtD
Fluvoxamine—Haematemesis—Varenicline—nicotine dependence	0.00764	0.00999	CcSEcCtD
Fluvoxamine—Suicidal ideation—Varenicline—nicotine dependence	0.00757	0.0099	CcSEcCtD
Fluvoxamine—Delusion—Varenicline—nicotine dependence	0.0075	0.00981	CcSEcCtD
Fluvoxamine—Hyperlipidaemia—Varenicline—nicotine dependence	0.00737	0.00963	CcSEcCtD
Fluvoxamine—Mania—Varenicline—nicotine dependence	0.0073	0.00954	CcSEcCtD
Fluvoxamine—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00726	0.0309	CbGpPWpGaD
Fluvoxamine—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00719	0.0306	CbGpPWpGaD
Fluvoxamine—Menorrhagia—Varenicline—nicotine dependence	0.00717	0.00938	CcSEcCtD
Fluvoxamine—Extrapyramidal disorder—Varenicline—nicotine dependence	0.00705	0.00922	CcSEcCtD
Fluvoxamine—Scotoma—Varenicline—nicotine dependence	0.00699	0.00914	CcSEcCtD
Fluvoxamine—Gingivitis—Varenicline—nicotine dependence	0.00676	0.00884	CcSEcCtD
Fluvoxamine—Mydriasis—Varenicline—nicotine dependence	0.00666	0.0087	CcSEcCtD
Fluvoxamine—Nephrolithiasis—Varenicline—nicotine dependence	0.0066	0.00863	CcSEcCtD
Fluvoxamine—CYP2B6—Xenobiotics—CYP2A7—nicotine dependence	0.00647	0.0275	CbGpPWpGaD
Fluvoxamine—Dysphonia—Varenicline—nicotine dependence	0.00645	0.00844	CcSEcCtD
Fluvoxamine—Endocrine disorder—Varenicline—nicotine dependence	0.0064	0.00837	CcSEcCtD
Fluvoxamine—CYP2E1—Xenobiotics—CYP2A7—nicotine dependence	0.00634	0.027	CbGpPWpGaD
Fluvoxamine—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.00633	0.0269	CbGpPWpGaD
Fluvoxamine—Acne—Varenicline—nicotine dependence	0.00631	0.00825	CcSEcCtD
Fluvoxamine—Aggression—Varenicline—nicotine dependence	0.00604	0.0079	CcSEcCtD
Fluvoxamine—Accidental injury—Varenicline—nicotine dependence	0.006	0.00784	CcSEcCtD
Fluvoxamine—CYP1A1—Xenobiotics—CYP2A7—nicotine dependence	0.00598	0.0254	CbGpPWpGaD
Fluvoxamine—Viral infection—Varenicline—nicotine dependence	0.00588	0.00768	CcSEcCtD
Fluvoxamine—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.00588	0.00768	CcSEcCtD
Fluvoxamine—Thinking abnormal—Varenicline—nicotine dependence	0.0058	0.00758	CcSEcCtD
Fluvoxamine—Nocturia—Varenicline—nicotine dependence	0.00572	0.00748	CcSEcCtD
Fluvoxamine—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00566	0.0241	CbGpPWpGaD
Fluvoxamine—Leukocytosis—Varenicline—nicotine dependence	0.00565	0.00738	CcSEcCtD
Fluvoxamine—Dysarthria—Varenicline—nicotine dependence	0.00561	0.00734	CcSEcCtD
Fluvoxamine—Coordination abnormal—Varenicline—nicotine dependence	0.00541	0.00707	CcSEcCtD
Fluvoxamine—Abnormal dreams—Varenicline—nicotine dependence	0.00525	0.00686	CcSEcCtD
Fluvoxamine—Eructation—Varenicline—nicotine dependence	0.00522	0.00682	CcSEcCtD
Fluvoxamine—Salivary hypersecretion—Varenicline—nicotine dependence	0.00516	0.00674	CcSEcCtD
Fluvoxamine—Photophobia—Varenicline—nicotine dependence	0.00498	0.00652	CcSEcCtD
Fluvoxamine—Dry eye—Varenicline—nicotine dependence	0.0049	0.00641	CcSEcCtD
Fluvoxamine—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00489	0.0208	CbGpPWpGaD
Fluvoxamine—Oesophagitis—Varenicline—nicotine dependence	0.00485	0.00634	CcSEcCtD
Fluvoxamine—Urine output increased—Varenicline—nicotine dependence	0.0048	0.00627	CcSEcCtD
Fluvoxamine—Mouth ulceration—Varenicline—nicotine dependence	0.0048	0.00627	CcSEcCtD
Fluvoxamine—Hypertonia—Varenicline—nicotine dependence	0.00465	0.00608	CcSEcCtD
Fluvoxamine—Mental disability—Varenicline—nicotine dependence	0.00461	0.00602	CcSEcCtD
Fluvoxamine—Euphoric mood—Varenicline—nicotine dependence	0.00456	0.00596	CcSEcCtD
Fluvoxamine—Lymphadenopathy—Varenicline—nicotine dependence	0.00452	0.0059	CcSEcCtD
Fluvoxamine—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.0045	0.0191	CbGpPWpGaD
Fluvoxamine—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00446	0.019	CbGpPWpGaD
Fluvoxamine—Sleep disorder—Varenicline—nicotine dependence	0.00445	0.00582	CcSEcCtD
Fluvoxamine—Diabetes mellitus—Varenicline—nicotine dependence	0.00443	0.00579	CcSEcCtD
Fluvoxamine—Polyuria—Varenicline—nicotine dependence	0.00439	0.00574	CcSEcCtD
Fluvoxamine—Deafness—Varenicline—nicotine dependence	0.00431	0.00563	CcSEcCtD
Fluvoxamine—Eczema—Varenicline—nicotine dependence	0.00429	0.00561	CcSEcCtD
Fluvoxamine—Eye pain—Varenicline—nicotine dependence	0.00427	0.00558	CcSEcCtD
Fluvoxamine—Injury—Varenicline—nicotine dependence	0.00419	0.00548	CcSEcCtD
Fluvoxamine—Renal failure acute—Varenicline—nicotine dependence	0.00417	0.00546	CcSEcCtD
Fluvoxamine—Libido decreased—Varenicline—nicotine dependence	0.00416	0.00543	CcSEcCtD
Fluvoxamine—Increased appetite—Varenicline—nicotine dependence	0.0041	0.00536	CcSEcCtD
Fluvoxamine—Amnesia—Varenicline—nicotine dependence	0.0041	0.00536	CcSEcCtD
Fluvoxamine—Visual disturbance—Varenicline—nicotine dependence	0.00407	0.00532	CcSEcCtD
Fluvoxamine—Thirst—Varenicline—nicotine dependence	0.00405	0.00529	CcSEcCtD
Fluvoxamine—Arthritis—Varenicline—nicotine dependence	0.00397	0.00518	CcSEcCtD
Fluvoxamine—Hypoglycaemia—Varenicline—nicotine dependence	0.00395	0.00516	CcSEcCtD
Fluvoxamine—Lethargy—Varenicline—nicotine dependence	0.00393	0.00514	CcSEcCtD
Fluvoxamine—Cerebrovascular accident—Varenicline—nicotine dependence	0.00393	0.00514	CcSEcCtD
Fluvoxamine—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00385	0.00504	CcSEcCtD
Fluvoxamine—Osteoarthritis—Varenicline—nicotine dependence	0.00385	0.00504	CcSEcCtD
Fluvoxamine—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00382	0.005	CcSEcCtD
Fluvoxamine—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00381	0.0162	CbGpPWpGaD
Fluvoxamine—Affect lability—Varenicline—nicotine dependence	0.00379	0.00496	CcSEcCtD
Fluvoxamine—Migraine—Varenicline—nicotine dependence	0.00379	0.00496	CcSEcCtD
Fluvoxamine—Psychotic disorder—Varenicline—nicotine dependence	0.00376	0.00492	CcSEcCtD
Fluvoxamine—Irritability—Varenicline—nicotine dependence	0.00368	0.00481	CcSEcCtD
Fluvoxamine—Urinary retention—Varenicline—nicotine dependence	0.00366	0.00479	CcSEcCtD
Fluvoxamine—Mood swings—Varenicline—nicotine dependence	0.00365	0.00477	CcSEcCtD
Fluvoxamine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00363	0.0155	CbGpPWpGaD
Fluvoxamine—CYP3A7—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00359	0.0153	CbGpPWpGaD
Fluvoxamine—Liver function test abnormal—Varenicline—nicotine dependence	0.00356	0.00465	CcSEcCtD
Fluvoxamine—Dry skin—Varenicline—nicotine dependence	0.00353	0.00462	CcSEcCtD
Fluvoxamine—Hypokalaemia—Varenicline—nicotine dependence	0.00351	0.00459	CcSEcCtD
Fluvoxamine—Breast disorder—Varenicline—nicotine dependence	0.00348	0.00455	CcSEcCtD
Fluvoxamine—Gastritis—Varenicline—nicotine dependence	0.00341	0.00446	CcSEcCtD
Fluvoxamine—Abdominal distension—Varenicline—nicotine dependence	0.00335	0.00438	CcSEcCtD
Fluvoxamine—Dysphagia—Varenicline—nicotine dependence	0.00333	0.00435	CcSEcCtD
Fluvoxamine—Asthma—Varenicline—nicotine dependence	0.00333	0.00435	CcSEcCtD
Fluvoxamine—Angina pectoris—Varenicline—nicotine dependence	0.00324	0.00424	CcSEcCtD
Fluvoxamine—Bronchitis—Varenicline—nicotine dependence	0.0032	0.00419	CcSEcCtD
Fluvoxamine—Abdominal discomfort—Varenicline—nicotine dependence	0.00319	0.00417	CcSEcCtD
Fluvoxamine—Pollakiuria—Varenicline—nicotine dependence	0.00308	0.00402	CcSEcCtD
Fluvoxamine—Erectile dysfunction—Varenicline—nicotine dependence	0.00307	0.00401	CcSEcCtD
Fluvoxamine—Photosensitivity reaction—Varenicline—nicotine dependence	0.00304	0.00397	CcSEcCtD
Fluvoxamine—Weight increased—Varenicline—nicotine dependence	0.00303	0.00396	CcSEcCtD
Fluvoxamine—Hyperglycaemia—Varenicline—nicotine dependence	0.003	0.00393	CcSEcCtD
Fluvoxamine—Depression—Varenicline—nicotine dependence	0.00296	0.00387	CcSEcCtD
Fluvoxamine—CYP3A7—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00295	0.0125	CbGpPWpGaD
Fluvoxamine—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00294	0.00385	CcSEcCtD
Fluvoxamine—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00294	0.0125	CbGpPWpGaD
Fluvoxamine—Acute coronary syndrome—Varenicline—nicotine dependence	0.00293	0.00383	CcSEcCtD
Fluvoxamine—Myocardial infarction—Varenicline—nicotine dependence	0.00291	0.00381	CcSEcCtD
Fluvoxamine—Stomatitis—Varenicline—nicotine dependence	0.00289	0.00378	CcSEcCtD
Fluvoxamine—Conjunctivitis—Varenicline—nicotine dependence	0.00289	0.00377	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Varenicline—nicotine dependence	0.00281	0.00367	CcSEcCtD
Fluvoxamine—Epistaxis—Varenicline—nicotine dependence	0.0028	0.00366	CcSEcCtD
Fluvoxamine—Sinusitis—Varenicline—nicotine dependence	0.00279	0.00364	CcSEcCtD
Fluvoxamine—Bradycardia—Varenicline—nicotine dependence	0.00271	0.00355	CcSEcCtD
Fluvoxamine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00269	0.0114	CbGpPWpGaD
Fluvoxamine—Hallucination—Varenicline—nicotine dependence	0.00265	0.00347	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Varenicline—nicotine dependence	0.00265	0.00347	CcSEcCtD
Fluvoxamine—CYP2B6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00265	0.0113	CbGpPWpGaD
Fluvoxamine—Urinary tract disorder—Varenicline—nicotine dependence	0.00263	0.00344	CcSEcCtD
Fluvoxamine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00263	0.0112	CbGpPWpGaD
Fluvoxamine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00263	0.0112	CbGpPWpGaD
Fluvoxamine—Oedema peripheral—Varenicline—nicotine dependence	0.00263	0.00343	CcSEcCtD
Fluvoxamine—Urethral disorder—Varenicline—nicotine dependence	0.00261	0.00342	CcSEcCtD
Fluvoxamine—CYP2E1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0026	0.0111	CbGpPWpGaD
Fluvoxamine—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00259	0.011	CbGpPWpGaD
Fluvoxamine—Visual impairment—Varenicline—nicotine dependence	0.00257	0.00336	CcSEcCtD
Fluvoxamine—Erythema multiforme—Varenicline—nicotine dependence	0.00252	0.0033	CcSEcCtD
Fluvoxamine—Eye disorder—Varenicline—nicotine dependence	0.00249	0.00326	CcSEcCtD
Fluvoxamine—Tinnitus—Varenicline—nicotine dependence	0.00249	0.00325	CcSEcCtD
Fluvoxamine—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00248	0.0106	CbGpPWpGaD
Fluvoxamine—Cardiac disorder—Varenicline—nicotine dependence	0.00247	0.00323	CcSEcCtD
Fluvoxamine—CYP1A1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00245	0.0104	CbGpPWpGaD
Fluvoxamine—Angiopathy—Varenicline—nicotine dependence	0.00242	0.00316	CcSEcCtD
Fluvoxamine—Chills—Varenicline—nicotine dependence	0.00239	0.00313	CcSEcCtD
Fluvoxamine—Arrhythmia—Varenicline—nicotine dependence	0.00238	0.00311	CcSEcCtD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00234	0.00994	CbGpPWpGaD
Fluvoxamine—Mental disorder—Varenicline—nicotine dependence	0.00234	0.00305	CcSEcCtD
Fluvoxamine—Malnutrition—Varenicline—nicotine dependence	0.00232	0.00303	CcSEcCtD
Fluvoxamine—Flatulence—Varenicline—nicotine dependence	0.00229	0.00299	CcSEcCtD
Fluvoxamine—Dysgeusia—Varenicline—nicotine dependence	0.00227	0.00297	CcSEcCtD
Fluvoxamine—Back pain—Varenicline—nicotine dependence	0.00225	0.00293	CcSEcCtD
Fluvoxamine—Muscle spasms—Varenicline—nicotine dependence	0.00223	0.00292	CcSEcCtD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.00222	0.00945	CbGpPWpGaD
Fluvoxamine—Vision blurred—Varenicline—nicotine dependence	0.00219	0.00286	CcSEcCtD
Fluvoxamine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00218	0.00927	CbGpPWpGaD
Fluvoxamine—Tremor—Varenicline—nicotine dependence	0.00217	0.00284	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Varenicline—nicotine dependence	0.00215	0.00282	CcSEcCtD
Fluvoxamine—Anaemia—Varenicline—nicotine dependence	0.00215	0.0028	CcSEcCtD
Fluvoxamine—CYP2E1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00213	0.00908	CbGpPWpGaD
Fluvoxamine—Agitation—Varenicline—nicotine dependence	0.00213	0.00279	CcSEcCtD
Fluvoxamine—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00213	0.00906	CbGpPWpGaD
Fluvoxamine—Angioedema—Varenicline—nicotine dependence	0.00212	0.00277	CcSEcCtD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.0021	0.00896	CbGpPWpGaD
Fluvoxamine—Malaise—Varenicline—nicotine dependence	0.00209	0.00274	CcSEcCtD
Fluvoxamine—Vertigo—Varenicline—nicotine dependence	0.00209	0.00273	CcSEcCtD
Fluvoxamine—Syncope—Varenicline—nicotine dependence	0.00208	0.00272	CcSEcCtD
Fluvoxamine—Palpitations—Varenicline—nicotine dependence	0.00205	0.00268	CcSEcCtD
Fluvoxamine—Loss of consciousness—Varenicline—nicotine dependence	0.00204	0.00267	CcSEcCtD
Fluvoxamine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00203	0.00864	CbGpPWpGaD
Fluvoxamine—Cough—Varenicline—nicotine dependence	0.00203	0.00265	CcSEcCtD
Fluvoxamine—CYP1A1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00201	0.00856	CbGpPWpGaD
Fluvoxamine—Convulsion—Varenicline—nicotine dependence	0.00201	0.00263	CcSEcCtD
Fluvoxamine—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.002	0.00853	CbGpPWpGaD
Fluvoxamine—Hypertension—Varenicline—nicotine dependence	0.002	0.00262	CcSEcCtD
Fluvoxamine—Myalgia—Varenicline—nicotine dependence	0.00198	0.00258	CcSEcCtD
Fluvoxamine—Arthralgia—Varenicline—nicotine dependence	0.00198	0.00258	CcSEcCtD
Fluvoxamine—Chest pain—Varenicline—nicotine dependence	0.00198	0.00258	CcSEcCtD
Fluvoxamine—Anxiety—Varenicline—nicotine dependence	0.00197	0.00257	CcSEcCtD
Fluvoxamine—Discomfort—Varenicline—nicotine dependence	0.00195	0.00255	CcSEcCtD
Fluvoxamine—Dry mouth—Varenicline—nicotine dependence	0.00193	0.00253	CcSEcCtD
Fluvoxamine—Oedema—Varenicline—nicotine dependence	0.00189	0.00248	CcSEcCtD
Fluvoxamine—Infection—Varenicline—nicotine dependence	0.00188	0.00246	CcSEcCtD
Fluvoxamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00187	0.00795	CbGpPWpGaD
Fluvoxamine—Shock—Varenicline—nicotine dependence	0.00186	0.00244	CcSEcCtD
Fluvoxamine—Nervous system disorder—Varenicline—nicotine dependence	0.00186	0.00243	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Varenicline—nicotine dependence	0.00185	0.00242	CcSEcCtD
Fluvoxamine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00185	0.00788	CbGpPWpGaD
Fluvoxamine—Tachycardia—Varenicline—nicotine dependence	0.00185	0.00242	CcSEcCtD
Fluvoxamine—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00184	0.00784	CbGpPWpGaD
Fluvoxamine—Hyperhidrosis—Varenicline—nicotine dependence	0.00183	0.00239	CcSEcCtD
Fluvoxamine—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00183	0.00777	CbGpPWpGaD
Fluvoxamine—Anorexia—Varenicline—nicotine dependence	0.00181	0.00236	CcSEcCtD
Fluvoxamine—Hypotension—Varenicline—nicotine dependence	0.00177	0.00231	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00173	0.00226	CcSEcCtD
Fluvoxamine—Insomnia—Varenicline—nicotine dependence	0.00171	0.00224	CcSEcCtD
Fluvoxamine—SLC6A3—Neuronal System—CHRNB3—nicotine dependence	0.0017	0.00724	CbGpPWpGaD
Fluvoxamine—Dyspnoea—Varenicline—nicotine dependence	0.00169	0.00221	CcSEcCtD
Fluvoxamine—Somnolence—Varenicline—nicotine dependence	0.00168	0.0022	CcSEcCtD
Fluvoxamine—Dyspepsia—Varenicline—nicotine dependence	0.00167	0.00218	CcSEcCtD
Fluvoxamine—CYP3A7—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00166	0.00706	CbGpPWpGaD
Fluvoxamine—Decreased appetite—Varenicline—nicotine dependence	0.00165	0.00215	CcSEcCtD
Fluvoxamine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00165	0.007	CbGpPWpGaD
Fluvoxamine—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00164	0.00214	CcSEcCtD
Fluvoxamine—Fatigue—Varenicline—nicotine dependence	0.00163	0.00213	CcSEcCtD
Fluvoxamine—Pain—Varenicline—nicotine dependence	0.00162	0.00212	CcSEcCtD
Fluvoxamine—Constipation—Varenicline—nicotine dependence	0.00162	0.00212	CcSEcCtD
Fluvoxamine—SLC6A3—Neuronal System—CHRNA6—nicotine dependence	0.00161	0.00686	CbGpPWpGaD
Fluvoxamine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00158	0.00673	CbGpPWpGaD
Fluvoxamine—CYP3A7—Biological oxidations—CYP2A7—nicotine dependence	0.00156	0.00666	CbGpPWpGaD
Fluvoxamine—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00156	0.00664	CbGpPWpGaD
Fluvoxamine—Feeling abnormal—Varenicline—nicotine dependence	0.00156	0.00204	CcSEcCtD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00156	0.00663	CbGpPWpGaD
Fluvoxamine—Gastrointestinal pain—Varenicline—nicotine dependence	0.00155	0.00202	CcSEcCtD
Fluvoxamine—CYP3A7—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00154	0.00657	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.00152	0.00648	CbGpPWpGaD
Fluvoxamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00151	0.00644	CbGpPWpGaD
Fluvoxamine—Urticaria—Varenicline—nicotine dependence	0.0015	0.00197	CcSEcCtD
Fluvoxamine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0015	0.00639	CbGpPWpGaD
Fluvoxamine—Abdominal pain—Varenicline—nicotine dependence	0.0015	0.00196	CcSEcCtD
Fluvoxamine—Body temperature increased—Varenicline—nicotine dependence	0.0015	0.00196	CcSEcCtD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.00146	0.00621	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00142	0.00602	CbGpPWpGaD
Fluvoxamine—Hypersensitivity—Varenicline—nicotine dependence	0.0014	0.00182	CcSEcCtD
Fluvoxamine—Asthenia—Varenicline—nicotine dependence	0.00136	0.00178	CcSEcCtD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.00136	0.00577	CbGpPWpGaD
Fluvoxamine—Pruritus—Varenicline—nicotine dependence	0.00134	0.00175	CcSEcCtD
Fluvoxamine—Diarrhoea—Varenicline—nicotine dependence	0.0013	0.00169	CcSEcCtD
Fluvoxamine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00128	0.00546	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00127	0.00542	CbGpPWpGaD
Fluvoxamine—Dizziness—Varenicline—nicotine dependence	0.00125	0.00164	CcSEcCtD
Fluvoxamine—CYP2B6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00123	0.00522	CbGpPWpGaD
Fluvoxamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00122	0.0052	CbGpPWpGaD
Fluvoxamine—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00121	0.00513	CbGpPWpGaD
Fluvoxamine—Vomiting—Varenicline—nicotine dependence	0.0012	0.00157	CcSEcCtD
Fluvoxamine—CYP2E1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.0012	0.00512	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.0012	0.00511	CbGpPWpGaD
Fluvoxamine—Rash—Varenicline—nicotine dependence	0.00119	0.00156	CcSEcCtD
Fluvoxamine—Dermatitis—Varenicline—nicotine dependence	0.00119	0.00156	CcSEcCtD
Fluvoxamine—Headache—Varenicline—nicotine dependence	0.00119	0.00155	CcSEcCtD
Fluvoxamine—SLC6A3—Neuronal System—GABRA4—nicotine dependence	0.00117	0.00496	CbGpPWpGaD
Fluvoxamine—CYP2B6—Biological oxidations—CYP2A7—nicotine dependence	0.00116	0.00492	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00114	0.00486	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00113	0.00482	CbGpPWpGaD
Fluvoxamine—CYP2E1—Biological oxidations—CYP2A7—nicotine dependence	0.00113	0.00482	CbGpPWpGaD
Fluvoxamine—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.00113	0.00481	CbGpPWpGaD
Fluvoxamine—Nausea—Varenicline—nicotine dependence	0.00113	0.00147	CcSEcCtD
Fluvoxamine—SLC6A3—Neuronal System—CHRNB4—nicotine dependence	0.00112	0.00476	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00112	0.00476	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00112	0.00475	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.00111	0.0047	CbGpPWpGaD
Fluvoxamine—CYP1A1—Biological oxidations—CYP2A7—nicotine dependence	0.00107	0.00455	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00105	0.00448	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neuronal System—CHRNA5—nicotine dependence	0.00104	0.00442	CbGpPWpGaD
Fluvoxamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00099	0.00421	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.000974	0.00414	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—DRD2—nicotine dependence	0.000941	0.004	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000928	0.00395	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.000884	0.00376	CbGpPWpGaD
Fluvoxamine—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.000874	0.00372	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000862	0.00367	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000853	0.00363	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neuronal System—CHRNA3—nicotine dependence	0.000847	0.0036	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000846	0.0036	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000804	0.00342	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.000797	0.00339	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000793	0.00338	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000786	0.00335	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neuronal System—CHRNB2—nicotine dependence	0.000746	0.00317	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000723	0.00308	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.000681	0.0029	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neuronal System—CHRNA4—nicotine dependence	0.000677	0.00288	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000672	0.00286	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000627	0.00267	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000558	0.00237	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000526	0.00224	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000519	0.00221	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000312	0.00133	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CYP2A7—nicotine dependence	0.000268	0.00114	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CYP2A7—nicotine dependence	0.000198	0.000842	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CYP2A7—nicotine dependence	0.000194	0.000825	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000193	0.000823	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CYP2A7—nicotine dependence	0.000183	0.000778	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.00015	0.000636	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000146	0.000621	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000138	0.000585	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000136	0.00058	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000117	0.000496	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP2A7—nicotine dependence	8.99e-05	0.000383	CbGpPWpGaD
